Content about Schering-Plough

August 23, 2010
Impax Labs pursuing FDA approval for generic cholesterol-lowering drug

Generic drug maker Impax Labs is hoping to win approval for a generic cholesterol-lowering drug....

August 1, 2010
Merck discloses Q2 earnings

Merck had global sales of $11.3 billion and profits of $752 million during second quarter...

July 6, 2010
Coppertone launches MyUVAlert app

Sun care brand Coppertone has developed an iPhone application to help consumers stay sun safe....

NEW YORK Sun care brand Coppertone has developed an iPhone application to help consumers stay sun safe.

With the Coppertone MyUVAlert app, consumers can get local UV index forecasts, custom sunscreen reapplication reminders, individualized product recommendations, coupons and sun protection tips.

The custom reapplication reminders allow for more frequent reminders when swimming or sweating and can be set based on activity or personal preferences.

June 23, 2010
Merck gets nod from FDA for Dulera

The Food and Drug Administration has approved a new drug by Merck for treating asthma...

June 6, 2010
Specialty Rx offers pharma a patent cliff parachute

While Big Pharma hurdles toward the edge of the patent cliff, some of the latest...

May 10, 2010
Glenmark, Par settle Zetia patent suit with Merck

Glenmark Generics has reached a settlement with Merck over a cholesterol drug, Glenmark partner Par...

May 9, 2010
Merck: Expanding investigational drug pipeline caused by Schering-Plough merger

Merck has more than 20 investigational drugs in late-stage development, thanks to its merger with...

March 23, 2010
University of Tennessee's pharmacy school receives $4.5 million donation

A pharmacy school in the Volunteer State has received a $4.5 million donation from the...

March 18, 2010
'Idol' judge announces partnership with Claritin

Claritin is teaming up with allergy sufferer and "American Idol" judge Kara DioGuardi around a...

March 14, 2010
Bausch & Lomb recruits two Schering-Plough leaders as CEO, chairman

Bausch & Lomb on Monday recruited two former Schering-Plough senior leaders to take the reigns...

March 14, 2010
Rx suppliers prepare for patent-protection storm

Drug companies stand to lose a lot of money in the coming years, as the...

March 11, 2010
CHPA honors Stan Barshay with outstanding achievement award

The Consumer Healthcare Products Association on Friday honored recently retired Stan Barshay, former chairman Schering-Plough...

February 28, 2010
Merck's R&D pipeline gets a boost

Merck & Co.’s acquisition of Schering-Plough has delivered a big boost to the drug maker’s...

February 16, 2010
Merck appoints EVP and president of consumer health care

Merck & Co. has appointed former Johnson & Johnson executive Bridgette Heller to serve as...

January 25, 2010
Teva wins patent battle over Merck's Temodar

Teva Pharmaceutical Industries may soon get the green light to market a generic drug for...

January 10, 2010
New P&G initiative may create clash of the OTC titans

This is shaping up to be a Fight Night dream card, with the battle arena...

WHAT IT MEANS AND WHY IT'S IMPORTANT This is shaping up to be a Fight Night dream card, with the battle arena located in the digestives aisle of a pharmacy near you. Are you ready to rumble?

(THE NEWS: P&G develops new program in line with Prilosec OTC. For the full story, click here)

January 10, 2010
Zegerid third PPI to go OTC

Zegerid OTC was approved for sale as a nonprescription remedy for frequent heartburn last month,...

December 3, 2009
Zegerid OTC approved as heartburn remedy

The digestives aisle will be altogether crowded come early 2010, especially with two new proton-pump...

NEW YORK The digestives aisle will be altogether crowded come early 2010, especially with two new proton-pump inhibitors on the shelf. And while there may be some question as to just how large sales of antacids can get, one thing is for sure: There will be a slew of advertisers vying for their own increased share of stomach.

June 28, 2009
Santarus announces Schering-Plough response submission to FDA for OTC Zegerid

There was speculation in January that Schering-Plough’s switch application around the proton-pump inhibitor Zegerid was...

NEW YORK There was speculation in January that Schering-Plough’s switch application around the proton-pump inhibitor Zegerid was scuttled after receiving a complete response letter from the Food and Drug Administration.

 

March 12, 2009
WMerck & Co. announces merger with Schering-Plough

The last few weeks have seen a lot of acquisition activity among large pharmaceutical companies....

The last few weeks have seen a lot of acquisition activity among large pharmaceutical companies.

 

First, Pfizer announced in January that it would acquire Wyeth for approximately $68 billion. This month saw three more mergers: Merck & Co.’s $41.1 billion purchase of Schering-Plough Corp., Roche’s $46.8 billion purchase of Genentech and Gilead Science’s purchase of CV Therapeutics.

 

January 11, 2009
Par reports Q1 results, enters partnership to develop Zetia generic

Par Pharmaceutical Cos. had total sales of $291.9 million and $26.3 million in profit for...